We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Audentes Therapeutics, Inc in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 186 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 188 → 0 (-188)

100% less funds holding in top 10

Funds holding in top 10: 19 → 0 (-19)

100% less capital invested

Capital invested by funds: $2.57B → $0 (-$2.57B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 186

Holders
–
Holders Change
-188
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-19
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
186
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$220M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$193M
3
MF
Magnetar Financial
Illinois
-$95.4M
4
AAM
Alpine Associates Management
Florida
-$87.1M
5
AA
AQR Arbitrage
Connecticut
-$81.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$32.1M -536,873 Closed
Northern Trust
27
Northern Trust
Illinois
– -$31.2M -521,541 Closed
Allianz Asset Management
28
Allianz Asset Management
Germany
– -$30M -501,401 Closed
DM
29
Deerfield Management
New York
– -$29.6M -493,901 Closed
CC
30
Carlson Capital
Texas
– -$28.8M -480,901 Closed
Tudor Investment Corp
31
Tudor Investment Corp
Connecticut
– -$27M -451,689 Closed
JP Morgan Chase
32
JP Morgan Chase
New York
– -$25.1M -419,221 Closed
RSCM
33
Rock Springs Capital Management
Maryland
– -$24.5M -410,000 Closed
MP
34
Manikay Partners
New York
– -$23.9M -400,000 Closed
BHMP
35
Bardin Hill Management Partners
New York
– -$20.3M -339,111 Closed
Morgan Stanley
36
Morgan Stanley
New York
– -$20.2M -336,931 Closed
GCIA
37
Gabelli & Co Investment Advisers
New York
– -$20M -334,869 Closed
PCM
38
Pentwater Capital Management
Florida
– -$19.8M -331,214 Closed
SG Americas Securities
39
SG Americas Securities
New York
– -$19.6M -326,905 Closed
EP
40
Eversept Partners
New York
– -$18.3M -305,726 Closed
SAM
41
Sandell Asset Management
New York
– -$18M -300,000 Closed
OM
42
Opaleye Management
Massachusetts
– -$17.5M -292,000 Closed
Charles Schwab
43
Charles Schwab
California
– -$16.8M -280,904 Closed
FIA
44
FNY Investment Advisers
New York
– -$16.7M -278,861 Closed
PCM
45
Prelude Capital Management
New York
– -$16.7M -278,465 Closed
CS
46
Credit Suisse
Switzerland
– -$16M -266,909 Closed
N
47
Nuveen
North Carolina
– -$16M -266,586 Closed
OAM
48
Oxford Asset Management
United Kingdom
– -$15.7M -261,538 Closed
CCM
49
Chicago Capital Management
Illinois
– -$15M -250,401 Closed
FCMI
50
Foresite Capital Management III
California
– -$13.9M -233,067 Closed
1
2
3 4 5

BOLD Hedge Fund Activity: Q1 2020 in Review

0 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2020, worth a combined $0 — down 100% from $2.57B a quarter earlier.

Sellers outnumbered buyers: 186 funds closed out of BOLD and 0 opened new positions — a net loss of 186 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $220M sold.

  • 0 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2020, down from 188 in Q4 2019.
  • Funds reported $0 of Audentes Therapeutics, Inc stock for Q1 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Audentes Therapeutics, Inc positions in Q1 2020 and 186 closed out, a net change of -186 holders.
  • The largest Audentes Therapeutics, Inc seller in Q1 2020 was BlackRock, an estimated $220M sold.

Based on aggregated 13F filings for Q1 2020.